The Institute of Cancer Research and Cancer Research Technology make European BRCA2 gene patent freely available
The Institute of Cancer Research and Cancer Research Technology (CRT), the technology transfer company of the charity Cancer Research UK, have announced the availability of free licences of European patents on the hereditary breast cancer gene BRCA2 to publicly funded research laboratories and not-for-profit research laboratories.
The patents are based on the pioneering work of Professor Mike Stratton undertaken at the Institute of Cancer Research and funded by CRT's parent charity, Cancer Research UK.
